Intercept Pharmaceuticals Inc
F:I4P
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Realty Income Corp
NYSE:O
|
Real Estate
|
| US |
|
Walt Disney Co
NYSE:DIS
|
Media
|
| US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
9.782
17.775
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
Abbvie Inc
NYSE:ABBV
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Realty Income Corp
NYSE:O
|
US |
|
|
Walt Disney Co
NYSE:DIS
|
US |
|
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intercept Pharmaceuticals Inc
Income from Continuing Operations
Intercept Pharmaceuticals Inc
Income from Continuing Operations Peer Comparison
ABBV
GILD
AMGN
VRTX
REGN
Competitive Income from Continuing Operations Analysis
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
I
|
Intercept Pharmaceuticals Inc
F:I4P
|
Income from Continuing Operations
-$57.5m
|
CAGR 3-Years
44%
|
CAGR 5-Years
30%
|
CAGR 10-Years
4%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Income from Continuing Operations
$5.4B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
5%
|
CAGR 10-Years
3%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Income from Continuing Operations
$1B
|
CAGR 3-Years
-41%
|
CAGR 5-Years
-30%
|
CAGR 10-Years
-18%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Income from Continuing Operations
$3.1B
|
CAGR 3-Years
-18%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
-5%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Income from Continuing Operations
-$489.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
1%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Income from Continuing Operations
$4.3B
|
CAGR 3-Years
-11%
|
CAGR 5-Years
17%
|
CAGR 10-Years
27%
|
See Also
What is Intercept Pharmaceuticals Inc's Income from Continuing Operations?
Income from Continuing Operations
-57.5m
USD
Based on the financial report for Sep 30, 2023, Intercept Pharmaceuticals Inc's Income from Continuing Operations amounts to -57.5m USD.
What is Intercept Pharmaceuticals Inc's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
4%
Over the last year, the Income from Continuing Operations growth was 72%. The average annual Income from Continuing Operations growth rates for Intercept Pharmaceuticals Inc have been 44% over the past three years , 30% over the past five years , and 4% over the past ten years .
You don't have any saved screeners yet
